BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a pharmaceutical company with a market capitalization of $14.83 million, announced today the implementation of a 1-for-16 reverse stock split of its common ...
(RTTNews) - BioXcel Therapeutics, Inc. (BTAI), Thursday announced a reverse stock split of 1-for-16 to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq ...
Following the reverse stock split, the company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "BTAI" with the new CUSIP number, 09075P204. The reverse stock split ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback